Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

References

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, New England Journal of Medicine	2012	12.5K
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Science	2004	9.4K
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Comprehensive molecular profiling of lung adenocarcinoma Nature	2014	5.7K
Mutational heterogeneity in cancer and the search for new cancer-associated genes Michael S. Lawrence, Petar Stojanov, Paz Polak, Nature	2013	5.6K
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, New England Journal of Medicine	2010	5.5K
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, The Lancet Oncology OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm	2012	5.5K

Page 1